Keep up-to-date with PrECOG by visiting our news page regularly.
PrECOG, LLC, collaborated with global partners on the first large, randomized phase 3 study to show a clinical benefit for CDK4/6 inhibition in HR+, HER2+ metastatic disease, resulting in a 15-month improvement in progression-free survival Philadelphia, PA, January 29, 2026 — PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 […]
The results from the PrE0204 trial, A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma was published by Sahai V, Catalano P, Zalupski MM, et.al. The article appeared online before print in JAMA Oncology on Aug 30, 2018. [NCT02181634, doi: 10.1001/jamaoncol.2018.3277].
The results from the PrE0102 study, a Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy was published by Kornblum N, Zhao F, Manola J, et.al. The article appeared online before print in the Journal of Clinical Oncology on April […]